Evaluating EVR to PEG IFN-α-2b/ribavirin therapy worthwhile

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.491, 2005-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PEG IFN-α-2b/ribavirin cost effective for HIV/HCV co-infection

By  

Inpharma, Vol. 1, Iss. 1522, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

PEG IFN-α-2b/ribavirin cost effective for HIV/HCV co-infection

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 495, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

PEG IFN- -2b + ribavirin superior for HCV + HIV infection

By  

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Monitoring early viral response to PEG IFN- -2b + ribavirin warranted

By  

Inpharma, Vol. 1, Iss. 1418, 2003-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

REPEAT reaffirms the benefits of retreatment with PEG IFN-α-2a

By  

Inpharma, Vol. 1, Iss. 1524, 2006-01 ,pp. : 13-14

Adis International

Access to resources Recommend Favorite